How we manage immune‐mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance
British Journal of Haematology · 2025-06 · 206 (6) · 1560-1570
DOI: 10.1111/bjh.20101 ↗At a glance
Übersichtsarbeit in British Journal of Haematology, published online on 2025-04-24. Written by Julia Weisinger and 4 co-authors. Institution: Centre de Référence des Microangiopathies Thrombotiques et Service d'hématologie, Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris and So…. Major MEDLINE topics: Rituximab, Purpura, Thrombotic Thrombocytopenic. Cited 12 times so far (Crossref); 63 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Plan for Rare Diseases of the French Ministry of Health, Filière de Santé Maladies Rares Immuno-Hématologiques, French Ministry of Health.
Abstract (original language)
The use of rituximab, a B‐cell‐depleting agent as a pre‐emptive treatment in immune‐mediated thrombotic thrombocytopenic purpura (iTTP), is the current standard of care. However, for patients refractory to rituximab or for those with contraindications, further treatment guidelines are scarce. Standard immunosuppressive or chemotherapeutic agents were used routinely in the past, but most of the data proving their efficacy are stemming from experience before the routine use of rituximab. Ciclosporin A and azathioprine seem to be effective in the pre‐emptive setting, but their safety profile might limit their use. Extended or intensive rituximab administration may overcome refractoriness in some patients. New therapeutic options, such as new generation anti‐CD20 antibodies like obinutuzumab or the plasma cell‐directed therapy daratumumab, showed important efficacy in iTTP after rituximab failure, with a favourable safety profile. There are no available comparative studies for pre‐emptive treatment options in iTTP; therefore, data from large databases and multicentre studies are essential. In this review, we summarize the possible treatment options in case of rituximab failure in iTTP and try to provide a recommendation based on available literature and our own experience.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Centre de Référence des Microangiopathies Thrombotiques et Service d'hématologie, Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris and Sorbonne Université, Paris, France.
- Service d'Immunologie Clinique, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
- INSERM Unité Mixte de Recherche (UMRS) 1138, Centre de Recherche des Cordeliers, Paris, France.
- Service d'Hématologie biologique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris Nord, Université Paris Cité, Paris, France.
ORCID profiles: Julia Weisinger, Paul Coppo
Funding
- National Plan for Rare Diseases of the French Ministry of Health
- Filière de Santé Maladies Rares Immuno-Hématologiques
- French Ministry of Health
- European Union MSCA TOLERATE
Cite
APA
Weisinger, J., Fadlallah, J., Joly, B., Veyradier, A., & Coppo, P. (2025). How we manage immune‐mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance. British Journal of Haematology, 206(6), 1560-1570. https://doi.org/10.1111/bjh.20101
Vancouver
Weisinger J, Fadlallah J, Joly B, Veyradier A, Coppo P. How we manage immune‐mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance. British Journal of Haematology. 2025;206(6):1560-1570. doi:10.1111/bjh.20101
BibTeX
@article{Weisinger2025,
author = {Weisinger, Julia and Fadlallah, Jehane and Joly, Bérangère and Veyradier, Agnès and Coppo, Paul},
title = {How we manage immune‐mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance},
journal = {British Journal of Haematology},
year = {2025},
volume = {206},
number = {6},
pages = {1560--1570},
doi = {10.1111/bjh.20101}
}
EUVIMED